Navigation Links
Pharmacyclics Reports Recent Developments and Financial Results for Fiscal Second Quarter 2011
Date:2/4/2011

to 40 patients and complete enrollment in the second half of calendar year 2011. We also plan to evaluate the safety of PCI-32765 in combination with several other common therapies in CLL and expect to begin enrollment in Q2 of calendar year 2011.-Diffuse Large B-Cell Lymphoma (DLBCL) Research has demonstrated that there are 2 distinct molecular subtypes in diffuse large B-cell lymphoma (ABC and GCB).  Activated B-cell, or ABC, is the poorer prognostic subtype and is characterized by activation of the B-cell receptor signaling pathway. Our Phase II program will evaluate 2 separate cohorts of patients with relapsed or refractory DLBCL who will receive single agent PCI-32765, those lymphoma patients with ABC and those with germinal center B-cell (GCB), the other molecular subtype. This study will evaluate safety and efficacy in approximately 60 patients. We anticipate that enrollment will begin during the first half of 2011. In parallel, we are also developing a Phase II safety trial combining PCI-32765 with chemotherapy in patients with relapsed or refractory DLBCL.


  • Abstract submitted to the 47th Annual Meeting of the American Society of Clinical Oncology (June 3 – 7, 2011) based on the Phase IB/II study data, evaluating safety and efficacy of administering the Btk Inhibitor, PCI-32765 as a single agent in CLL/SLL patients

  • Poster presentation at the 2011 GI Cancers Symposium of first in human Phase I results of Factor VIIa Inhibitor, PCI-27483 In the Phase I portion of the study, ascending repeated doses of PCI-27483 (dosages ranging from 0.8 to 1.5 mg/kg) were evaluated in 8 patients with pancreatic cancer receiving concomitant gemcitabine chemotherapy. Among the 5 patients in Phase I considered evaluable, all 5 had stable disease at week 12 and opted to extend treatment with PCI-27483. Three of the 5 patients have a progression free survival > / = 30 weeks (7 months). None
    '/>"/>


  • SOURCE Pharmacyclics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related biology technology :

    1. Pharmacyclics Announces Date of Fourth Quarter and Fiscal Year End 2009 Conference Call
    2. Pharmacyclics to Present and Webcast at Upcoming Life Sciences Investor Conferences
    3. Pharmacyclics, Inc. Rights Offering Oversubscribed
    4. Pharmacyclics Announces Subscription Price for Rights Offering
    5. Pharmacyclics to Present at the 8th Annual Needham and Company Life Sciences Conference
    6. Pharmacyclics Files Registration Statement for Rights Offering
    7. Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
    8. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
    9. Pharmacyclics Secures $5.0 Million in Debt Financing
    10. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
    11. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/22/2015)... CAMBRIDGE, Mass. , Jan. 22, 2015   GenoSpace , ... suite of tools to enable the broad use of genomic, ... today announced the appointment of Michelle Munson , CEO ... independent director. Logo - http://photos.prnewswire.com/prnh/20150122/170713 ...
    (Date:12/24/2014)... 24, 2014  United Therapeutics Corporation (NASDAQ: UTHR ... MDT ) has submitted a pre-market approval application to ... use of Medtronic,s SynchroMed ® II implantable drug ... with United Therapeutics, Remodulin ® (treprostinil) Injection delivered ...
    (Date:12/24/2014)...   BioLife Solutions , Inc. (NASDAQ: BLFS ), ... hypothermic storage and cryopreservation freeze media ... tissues  ("BioLife" or the "Company"), today announced that it will ... 2015 (the "Annual Meeting"). Because the expected date ...
    (Date:12/24/2014)... (PRWEB) December 23, 2014 Earlier this year ... Sherley, director of the Adult Stem Cell Technology Center, LLC ... under appreciated unique property of adult tissue stem cells. ... the Past, Important for the Future,” embodied the essence of ...
    Breaking Biology Technology:GenoSpace Expands Board with Appointment of Michelle Munson 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4
    ... and Dane County directory of high-technology companies was released ... and the City of Madisons office of business resources, ... High-Tech Companies is designed to provide both company ... ,Jim Mohrbacher, MG&E business development manager, who coordinates the ...
    ... Three large U.S. manufacturing companies announced Wednesday that they ... Partnership to help U.S.-based suppliers adopt best practices ... , Deere & Company and Oshkosh ... Matters Conference in Milwaukee, attended by 500 Wisconsin manufacturing ...
    ... The University of Wisconsin-Madison Medical School has a ... million, 160,600-square-foot building that will unify the health sciences on ... the future of medicine, said Paul DeLuca , associate ... , ,The center will bring together medicine, nursing, pharmacy and ...
    Cached Biology Technology:Dane Country high-tech businesses continue to flourish 2Dane Country high-tech businesses continue to flourish 3Manufacturers join Wisconsin partnership to boost U.S. suppliers 2UW Medical School to build Health Sciences Learning Center 2
    (Date:1/22/2015)... 16, 2015  A man-made form of insulin delivered by ... capabilities in adults with mild cognitive impairment and Alzheimer,s ... researchers at Wake Forest Baptist Medical Center. ... mild cognitive impairment (MCI) or mild to moderate Alzheimer,s ...
    (Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... of the "Global Wearable Technologies Market and ... Overview, Trends and Forecast 2014-2020" report to ... are smart devices that can be worn on ...
    (Date:12/22/2014)... 22, 2014 Research and Markets ( ... "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight provides ... and fingerprinting markets. Watermarking aims to control and ...
    Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2The Global Watermarking and Fingerprinting Markets 2
    ... first pandemic in the early 19th century it has ... The Hebrew University of Jerusalem, Israel, the lethal infection ... Lerner explains that the females contaminate water sources with ... that his colleagues Nikolay Meltser and Meir Broza had ...
    ... 30 -- Two groups of researchers, one in the ... development of new optical techniques for visualizing the invisible ... results are the first to showcase the Optical Society,s ... to submit a manuscript that includes large three-dimensional data ...
    ... The world,s rarest big cat is alive and well. ... from the Wildlife Conservation Society (WCS) who captured and released ... capture was made in Primorsky Krai along the Russian-Chinese border ... Academy of Sciences Institute of Biology and Soils (IBS). ...
    Cached Biology News:Polarized light guides cholera-carrying midges that contaminate water supplies 2OSA's ISP launches with research on breathing disorders and congenital heart defects 2OSA's ISP launches with research on breathing disorders and congenital heart defects 3OSA's ISP launches with research on breathing disorders and congenital heart defects 4World's rarest big cat gets a check-up 2World's rarest big cat gets a check-up 3
    ... Freedom EVO96R and Freedom EVO384R are fast ... available in three different sizes, with a ... They deliver significant time saving, with true ... easy setup of your assays with the ...
    Designed for use with any of the Agencourt kits in tube format....
    ... is a fluorescent counterstain which ... color. The bright blue fluorescence ... fluorochromes such as rhodamine, Cy3, ... can be used for fluorescent ...
    ... P450 (CYP450) metabolite postulated to play an ... vasculature. In rat cerebral microvessels, 20-HETE is ... 20-HETE is excreted mainly as the glucuronide ... pg/ml in human urine) is about 10-fold ...
    Biology Products: